Our Impact

$517,500

The research study entitled, Developing Human Cellular Models of Aging and Alzheimer’s Disease, led by Dr. Bruce Yankner, Professor of Genetics and Neurology at Harvard Medical School, Director of the Harvard Neurodegeneration Training Program, and Co-Director of the Paul F. Glenn Center for Biology of Aging. Dr. Yankner has received several awards including the Zenith Award from the Alzheimer’s Association, the Nathan W. Shock award from NIA, and the NIH Director’s Pioneer Award and Transformative Research Award
Investigate a new molecular pathway using human brain cell models which will focus on understanding the earliest changes in the aging brain that lead to Alzheimer’s disease, as well as new preventative and therapeutic strategies

$584,622

The research study entitled, In vivo assessment of neuroimmune response to AD pathology and neurodegeneration, led by Dr. Victor L. Villemagne, recognized as one of “The World’s Most Influential Scientific Mind” based on his citations ranking in the top 1% globally in the field of Neuroscience and currently ranked #19 in the world among Alzheimer’s disease experts (2022)
Ascertain the association of astrogliosis with Alzheimer’s disease pathology, cerebrovascular disease, and neuro degeneration, which will provide critical knowledge for the design of future preventative strategies for Alzheimer’s disease

$296,215

The research study entitled, Circulating Inflammatory Factors in Early Stage Dementia, led by Dr. Lynn Bekris, co-director of the Cleveland Clinic Lou Ruvo Center for Brain Health Aging and Neurodegeneration Biobank and Cleveland Alzheimer’s Disease Research Center Biomarker Core Director
Identify and define key inflammatory factors that are active in the early stages of dementia

$500,000

The research study entitled, Alzheimer’s-related endosomal dysfunction and CSF tau, led by Dr. Scott Small, Director of the National Institute of Aging Alzheimer’s Disease Research Center (ADRC) at Columbia University
Investigate the cause of cerebro-spinal fluid elevation of the protein tau in Alzheimer Disease and to further research on the trafficking hypothesis as the cause of Alzheimer’s disease

$600,000

The research study entitled, High Fidelity Alzheimer’s Disease Models for Pathophysiological Investigation and Therapeutic Development, led by Dr. Stephen M. Strittmatter Director of Yale University School of Medicine’s Cellular Neuroscience, Neurodegeneration and Repair Program
Develop therapeutic methods to protect synapses, the specialized connections between nerve cells, from Amyloid-beta triggered degeneration. Success will rescue the brain’s neural network from Alzheimer-associated damage without a need to remove or reduce Amyloid itself

$700,000

The research study entitled, Presymptomatic Diagnosis of Alzheimer’s Disease and Other Tauopathies, led by Dr. Marc Diamond, Director of the Center for Alzheimer’s, and Neurodegenerative Diseases
Identify molecular mechanisms and therapeutic targets that play a key role in the pathogenesis of Alzheimer’s disease. The research also seeks to develop new therapies and diagnostics for Alzheimer’s that will allow diagnosis and treatment in people before the onset of cognitive problems

$398,757

The research study entitled, Early Onset Alzheimer’s Disease Genomic Study, led by Dr. Claudia Padilla and the research study entitled Pilot study of Triheptanoin in patients with mild impairment, led by Dr. Terry Bottiglieri, Center Director for Research, Dr. Claudia Padilla, neurologist, and Dr. Cindy Marshall, Director of the Baylor Neuroscience Center’s AT&T Memory Center
Conduct a gene sequencing study on “outlier” Alzheimer’s patients, so that the disease can be predicted because of a known genetic mutation. The research seeks to ascertain differences in metabolites between the normal brain and an Alzheimer’s disease brain to help identify affected pathways and lead to the possible development of targeted therapies

$220,000

The research study led by Dr. Namrata Singh and by Dr. Das, part of The University of Texas at Dallas’ School of Behavioral and Brain Sciences.
Explore cognitive behavior and other biomarkers found in early mild cognitive impairment by using experimental modalities

$208,950

The research study led by Dr. Sara Festini, specializing in cognitive psychology and cognitive neuroscience and Dr. Koen, post-doctoral scientist, and Dr. Michael Rugg, Distinguished Chair in Behavioral and Brain Science and Director of Center for Vital Longevity, University of Texas at Dallas
Support research to further advancements in the field of cognitive neuroscience of aging which focuses on cognition and brain function in busy people versus people who are less active and more relaxed

Aging Mind Foundation